Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium falciparum Circumsporozoite Protein ICC-1132 Alum USA Phase1 Trial
2008

Phase I Trial of a Malaria Vaccine Using Hepatitis B Core Particles

Sample size: 51 publication 10 minutes Evidence: moderate

Author Information

Author(s): Gregson Aric L., Oliveira Giane, Othoro Caroline, Calvo-Calle J. Mauricio, Thorton George B., Nardin Elizabeth, Edelman Robert

Primary Institution: University of Maryland School of Medicine

Hypothesis

The study aims to assess the safety, reactogenicity, and immunogenicity of the ICC-1132 malaria vaccine adjuvanted with Alhydrogel.

Conclusion

The candidate malaria vaccine ICC-1132 was well tolerated but showed poor immunogenicity.

Supporting Evidence

  • 95 to 100% of volunteers developed antibody responses to the ICC-1132 immunogen after two injections.
  • Only 29-75% of volunteers developed malaria-specific responses.
  • Local and systemic reactions were mild and well tolerated across dose cohorts.

Takeaway

Researchers tested a new malaria vaccine on healthy adults, and while it was safe, it didn't make people immune to malaria as well as hoped.

Methodology

This was a non-randomized, non-blinded, dose-escalating Phase I clinical trial assessing the vaccine's safety and immune response in healthy adults.

Potential Biases

The study was not blinded after the saline formulation was removed, which may introduce bias in reporting adverse events.

Limitations

The vaccine formulation was poorly immunogenic, and the malaria challenge trial was cancelled due to insufficient immunogenicity.

Participant Demographics

Participants were healthy, malaria-naive adults aged 18 to 45, with a median age of 25 years.

Statistical Information

P-Value

0.02

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0001556

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication